News & Events

• March 11, 2018
  

  D-RSC presents poster on advancing drug development for Duchenne through data sharing and quantitative tool development at the 2018 MDA Clinical Conference

• March 8, 2018
  

  Quantitative Approach for Cardiac Risk Assessment and Interpretation in Tuberculosis Drug Development

  Polak S, Romero K, Berg A, Patel N, Jamei M, Hermann D, et al. Quantitative approach for cardiac risk assessment and interpretation in tuberculosis drug development. J Pharmacokinet Pharmacodyn. 2018 Mar 8;1–11.

• February 27, 2018
  

  Patient-Reported Outcome (PRO) Consortium Translation Process: Consensus Development of Updated Best Practices

  Eremenco S, Pease S, Mann S, Berry P, on behalf of the PRO Consortium’s Process Subcommittee. Patient-Reported Outcome (PRO) Consortium translation process: consensus development of updated best practices. Journal of Patient-Reported Outcomes. 2017;(2):12.

• February 20, 2018
  

  2018 ISCTM Distinguished Poster Award Winner: “Global Regulatory Agencies Support Dopamine Transporter Neuroimaging in Clinical Trials Targeting Parkinson’s disease”

• February 12, 2018
  

  Tucson-based Critical Path Institute emerging as top drug-research organization

  President and CEO Dr. Martha Brumfield was recently interviewed by the Arizona Daily Star for a profile on C-Path published February 11. Dr. Brumfield discusses C-Path’s local ties,expanding global reach, and its recent successes, as well as its groundbreaking collaborative research model. The story outlines the work of C-Path’s consortia in the areas of biomarker...